Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Sell
45
CNVVY Quote, Financials, Valuation and Earnings
Last price:
$13.68
Seasonality move
:
7.4%
Day range:
$13.43 - $13.81
52-week range:
$10.77 - $15.40
Dividend yield:
1.84%
P/E ratio:
37.12x
P/S ratio:
3.10x
P/B ratio:
4.18x
Volume:
3.5K
Avg. volume:
41K
1-year change:
-6.5%
Market cap:
$7.1B
Revenue:
$2.3B
EPS (TTM):
$0.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CNVVY
ConvaTec Group PLC
|
-- | -- | -- | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$7M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
AUTL
Autolus Therapeutics PLC
|
$1.6M | -$0.26 | -84.24% | -7.08% | $10.10 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$53.6M | -$0.03 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CNVVY
ConvaTec Group PLC
|
$13.81 | -- | $7.1B | 37.12x | $0.07 | 1.84% | 3.10x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.25 | $1.71 | $64.3M | -- | $0.00 | 0% | 0.36x |
|
AUTL
Autolus Therapeutics PLC
|
$1.41 | $10.10 | $375.2M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.20 | $17.97 | $802.3K | -- | $0.00 | 0% | 1.11x |
|
NCNA
NuCana PLC
|
$0.89 | $104.00 | $5.4M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$58.54 | $81.00 | $5B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CNVVY
ConvaTec Group PLC
|
39.93% | 0.777 | 19.2% | 0.75x |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 4.133 | 36.44% | 2.60x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 2.712 | -- | 10.47x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 1.825 | -- | 1.20x |
|
NCNA
NuCana PLC
|
-- | 0.371 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | 0.836 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CNVVY
ConvaTec Group PLC
|
-- | -- | 6.56% | 11.35% | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$75.9M | -51.91% | -51.91% | -196479.31% | -$61.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
ConvaTec Group PLC vs. Competitors
-
Which has Higher Returns CNVVY or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to ConvaTec Group PLC's net margin of -2303.38%. ConvaTec Group PLC's return on equity of 11.35% beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital CNVVYConvaTec Group PLC-- -- $2.8B ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About CNVVY or ADAP?
ConvaTec Group PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 582.5%. Given that Adaptimmune Therapeutics PLC has higher upside potential than ConvaTec Group PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than ConvaTec Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings CNVVYConvaTec Group PLC0 0 0 ADAPAdaptimmune Therapeutics PLC2 2 0 -
Is CNVVY or ADAP More Risky?
ConvaTec Group PLC has a beta of 0.945, which suggesting that the stock is 5.494% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.845, suggesting its more volatile than the S&P 500 by 184.488%.
-
Which is a Better Dividend Stock CNVVY or ADAP?
ConvaTec Group PLC has a quarterly dividend of $0.07 per share corresponding to a yield of 1.84%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ConvaTec Group PLC pays 68.35% of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend. ConvaTec Group PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CNVVY or ADAP?
ConvaTec Group PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. ConvaTec Group PLC's net income of -- is lower than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, ConvaTec Group PLC's price-to-earnings ratio is 37.12x while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ConvaTec Group PLC is 3.10x versus 0.36x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNVVYConvaTec Group PLC3.10x 37.12x -- -- ADAPAdaptimmune Therapeutics PLC0.36x -- $3.2M -$74.2M
-
Which has Higher Returns CNVVY or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to ConvaTec Group PLC's net margin of -95193.1%. ConvaTec Group PLC's return on equity of 11.35% beat Autolus Therapeutics PLC's return on equity of -51.91%.
Company Gross Margin Earnings Per Share Invested Capital CNVVYConvaTec Group PLC-- -- $2.8B AUTLAutolus Therapeutics PLC-- -$0.09 $427.3M -
What do Analysts Say About CNVVY or AUTL?
ConvaTec Group PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.10 which suggests that it could grow by 616.31%. Given that Autolus Therapeutics PLC has higher upside potential than ConvaTec Group PLC, analysts believe Autolus Therapeutics PLC is more attractive than ConvaTec Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings CNVVYConvaTec Group PLC0 0 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is CNVVY or AUTL More Risky?
ConvaTec Group PLC has a beta of 0.945, which suggesting that the stock is 5.494% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.063, suggesting its more volatile than the S&P 500 by 106.26%.
-
Which is a Better Dividend Stock CNVVY or AUTL?
ConvaTec Group PLC has a quarterly dividend of $0.07 per share corresponding to a yield of 1.84%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ConvaTec Group PLC pays 68.35% of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend. ConvaTec Group PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CNVVY or AUTL?
ConvaTec Group PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $29K. ConvaTec Group PLC's net income of -- is lower than Autolus Therapeutics PLC's net income of -$27.6M. Notably, ConvaTec Group PLC's price-to-earnings ratio is 37.12x while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ConvaTec Group PLC is 3.10x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNVVYConvaTec Group PLC3.10x 37.12x -- -- AUTLAutolus Therapeutics PLC-- -- $29K -$27.6M
-
Which has Higher Returns CNVVY or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to ConvaTec Group PLC's net margin of --. ConvaTec Group PLC's return on equity of 11.35% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital CNVVYConvaTec Group PLC-- -- $2.8B BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About CNVVY or BDRX?
ConvaTec Group PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 1407.64%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than ConvaTec Group PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than ConvaTec Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings CNVVYConvaTec Group PLC0 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is CNVVY or BDRX More Risky?
ConvaTec Group PLC has a beta of 0.945, which suggesting that the stock is 5.494% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.705, suggesting its more volatile than the S&P 500 by 70.482%.
-
Which is a Better Dividend Stock CNVVY or BDRX?
ConvaTec Group PLC has a quarterly dividend of $0.07 per share corresponding to a yield of 1.84%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ConvaTec Group PLC pays 68.35% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. ConvaTec Group PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CNVVY or BDRX?
ConvaTec Group PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. ConvaTec Group PLC's net income of -- is lower than Biodexa Pharmaceuticals PLC's net income of --. Notably, ConvaTec Group PLC's price-to-earnings ratio is 37.12x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ConvaTec Group PLC is 3.10x versus 1.11x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNVVYConvaTec Group PLC3.10x 37.12x -- -- BDRXBiodexa Pharmaceuticals PLC1.11x -- -- --
-
Which has Higher Returns CNVVY or NCNA?
NuCana PLC has a net margin of -- compared to ConvaTec Group PLC's net margin of --. ConvaTec Group PLC's return on equity of 11.35% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNVVYConvaTec Group PLC-- -- $2.8B NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About CNVVY or NCNA?
ConvaTec Group PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 11585.39%. Given that NuCana PLC has higher upside potential than ConvaTec Group PLC, analysts believe NuCana PLC is more attractive than ConvaTec Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings CNVVYConvaTec Group PLC0 0 0 NCNANuCana PLC0 1 0 -
Is CNVVY or NCNA More Risky?
ConvaTec Group PLC has a beta of 0.945, which suggesting that the stock is 5.494% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.355%.
-
Which is a Better Dividend Stock CNVVY or NCNA?
ConvaTec Group PLC has a quarterly dividend of $0.07 per share corresponding to a yield of 1.84%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ConvaTec Group PLC pays 68.35% of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend. ConvaTec Group PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CNVVY or NCNA?
ConvaTec Group PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. ConvaTec Group PLC's net income of -- is lower than NuCana PLC's net income of -$836.1K. Notably, ConvaTec Group PLC's price-to-earnings ratio is 37.12x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ConvaTec Group PLC is 3.10x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNVVYConvaTec Group PLC3.10x 37.12x -- -- NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns CNVVY or VRNA?
Verona Pharma PLC has a net margin of -- compared to ConvaTec Group PLC's net margin of -92.29%. ConvaTec Group PLC's return on equity of 11.35% beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital CNVVYConvaTec Group PLC-- -- $2.8B VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About CNVVY or VRNA?
ConvaTec Group PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 38.37%. Given that Verona Pharma PLC has higher upside potential than ConvaTec Group PLC, analysts believe Verona Pharma PLC is more attractive than ConvaTec Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings CNVVYConvaTec Group PLC0 0 0 VRNAVerona Pharma PLC5 0 0 -
Is CNVVY or VRNA More Risky?
ConvaTec Group PLC has a beta of 0.945, which suggesting that the stock is 5.494% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.165, suggesting its less volatile than the S&P 500 by 83.527%.
-
Which is a Better Dividend Stock CNVVY or VRNA?
ConvaTec Group PLC has a quarterly dividend of $0.07 per share corresponding to a yield of 1.84%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ConvaTec Group PLC pays 68.35% of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend. ConvaTec Group PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CNVVY or VRNA?
ConvaTec Group PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. ConvaTec Group PLC's net income of -- is lower than Verona Pharma PLC's net income of -$33.8M. Notably, ConvaTec Group PLC's price-to-earnings ratio is 37.12x while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ConvaTec Group PLC is 3.10x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNVVYConvaTec Group PLC3.10x 37.12x -- -- VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
